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Abstract
Background: Human Cytomegalovirus (HCMV) is the most common cause of congenital infections. The maternal
immune status plays a major role in the likelihood of congenital infection. The aim of this study is to shed light on
the seroprevalence of HCMV in pregnant women, hospitalized children and newborns including cases of congenital
infections in Palestine.
Methods: We analyzed HCMV IgG and IgM test results that had been ordered for pregnant women, hospitalized
children and newborns in the years 2006–2012 at Al-Makassed Islamic Charitable Hospital (MICH) in East Jerusalem.
Furthermore, we reviewed the medical charts of newborns and HCMV IgM-positive children.
Results: HCMV IgG was positive in 96.6% of pregnant women, in 88% of hospitalized children and in 98.4% of
hospitalized newborns. HCMV IgM was positive in 11.5% of pregnant women, in 11.7% of hospitalized children and
in 2% of hospitalized newborns respectively. The HCMV avidity assay revealed that 95% of IgM-positive pregnant
women had high avidity (>60%) indicating that most Palestinian women were undergoing a recurrent HCMV infection.
Real time PCR on limited number of cases indicated that 62.5% of infants, mostly born to IgM-positive mothers and
83.3% of HCMV IgM-positive children had detectable HCMV DNA in their urine. Out of the 249 newborns tested during
this study period, four (1.6%) were subjected to Gancyclovir treatment because of symptomatic congenital HCMV infection.
Conclusions: This is the first report to provide an insight into HCMV seroprevalence in Palestine. Despite the high rate of
seropositivity, the importance of HCMV testing during pregnancy should not be underestimated. A comprehensive study
with a long term follow-up examination of offspring born to HCMV IgM-positivemothers would be required to provide
estimates of an accurate percentage of symptomatic congenital HCMV infection in Palestine.
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Background
Some of the most common infections associated with
congenital anomalies are summarized in TORCH testing.
TORCH includes Toxoplasmosis, Other (syphilis, varicella-
zoster, parvovirus B19, Hepatitis B), Rubella, Cytomegalo-
virus (CMV), and Herpesvirus infections. Most of the
TORCH infections cause mild maternal morbidity. How-
ever, they may have very serious consequences in the fetus,
with a high rate of congenital anomalies, mental retard-
ation, and an increased incidence of stillbirths [1,2].
Human cytomegalovirus (HCMV), HHV-5, belongs to
the beta herpes family and is one of the most common
causes of congenital viral infections. Congenital HCMV
infection is associated with permanent hearing loss,
vision loss and neurological impairment [3-5]. Maternal
sexual behavior and contact with infected young chil-
dren are the common source of infection [6]. Vertical
transmission of HCMV to the fetus can be attributed
to either recurrent maternal infection [7,8], or primary
maternal infection [9]. Recurrent infection is the result
of two possibilities: a reactivation of latent virus acquired
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prior to pregnancy or a reinfection with a new HCMV
strain during pregnancy [10]. Compared with recurrent
infection, primary HCMV infection accounts for the
highest transplacental transmission rate to the fetus,
causing a high likelihood of fetal damage [9,11-13].
Furthermore, the gestational age at which primary
HCMV infection occurs is crucial; the earlier the infec-
tion occurs during pregnancy, the more severe the con-
sequences [9,14,15].
The seroprevalence of HCMV is generally high in
developing countries, and among those of lower socio-
economic status in developed countries [16]. HCMV
seroprevalence status among pregnant and childbearing
age women is the main focus of various worldwide stud-
ies due to the severe consequences to offspring. A rela-
tively low seroprevalence, 40%-60%, is reported from
Australia, Belgium, France, Germany and USA [17-23].
A high HCMV seroprevalence (>90%) is reported from
Brazil, Taiwan [24-27] and in regional countries includ-
ing Turkey, Qatar and Saudi Arabia [28-31]. Reports
from USA and Israel indicate that the HCMV seropreva-
lence among women varies based on ethnical and/or
racial groups [32-34].
In this study, we analyzed the results of HCMV-
specific IgG and IgM assays at Al-Makassed Islamic
Charitable Hospital (MICH) in East Jerusalem, the refer-
ral hospital in Palestine, and from the limited number of
HCMV viral load records maintained at the Virology
Research Laboratory, Medical Research Center, Al-Quds
University, East Jerusalem, Palestine. The data presented
here shed light on the incidence of HCMV infection in
pregnant Palestinian women, children and newborns.
Methods
Study population
MICH is the referral hospital for Palestine and the main
teaching hospital associated with Al-Quds University
Medical School. Accordingly, patients visiting the hos-
pital come from all over the West Bank, East Jerusalem
and the Gaza strip. However, most pregnant women
seeking consultation at MICH are predominantly resi-
dents of East Jerusalem district. The range of monthly
deliveries at MICH is 180–200, most of which are not
booked, i.e. they did not consult the MICH outpatient
clinic during pregnancy. HCMV IgG and IgM tests were
ordered routinely for pregnant women as part of TORCH
surveillance. The age of pregnant women ranged from
17–45 years with the majority in their twenties and
thirties. The TORCH test was ordered for children mainly
if they presented with jaundice and/or prolonged fever of
unknown origin. The age of children was between one
month and 14 years. In case of newborns, HCMV IgG and
IgM tests were ordered either as part of TORCH surveil-
lance if any clinical manifestation suggestive of congenital
infection was observed, or because they were offspring
of HCMV IgM-positive mothers, even when signs of
congenital infection were absent. Newborns were between
one and 21 days old and were mainly tested using their
mother’s name as identification as most of them had not
yet been determined.
Ethical approval
Patients’ data and results were made available by the
director of the MICH Central Laboratory and approved
by the MICH Ethics Committee. Reviewing medical files
was approved by the MICH Ethics Committee.
HCMV IgG and IgM tests
IgG and IgM were tested from serum samples using
AxSYM kits (CMV IgG; 34-1685/R7 and IgM; 34-3532/
R6) on Abbott AxSYM machine according to the manu-
facturer instructions. Tests were performed at the MICH
Central Laboratory. The laboratory participates regularly
in internationally recognized external quality control
(Labquality, Helsinki, Finland) for HCMV serology three
times annually.
Avidity test
HCMV IgG avidity assay was performed on IgM-positive
serum samples using Anti-CMV ELISA (EUROIMMUN
Medizinische Labordiagnostika AG, Lübeck, Germany).
HCMV IgG avidity assay had been introduced into the
test list of the MICH Central Laboratory in January,
2012. The laboratory participates in internationally rec-
ognized external quality control (Labquality, Helsinki,
Finland) for HCMV IgG avidity once annually.
Real time PCR
Real time PCR for HCMV was performed at the Virology
Laboratory at Al-Quds University. DNA was isolated from
urine or whole blood, serum or urine samples using
the QIAamp DNA Blood Mini Kit (cat#51304, Qiagen,
Hilden, Germany). Real time PCR for viral load detection
was performed using an ABI Real Time PCR 7500
(Applied Biosystems, USA). The reaction included TaqMan
universal master mix (Applied Biosystems), CMV –gB-F:
5′-TGG GCG AGG ACA ACG AAA TC-3′, CMV –gB-R:
5′-TGA GGC TGG GAA GCT GAC AT-3′ as primer
and 5′(FAM) -TGG GCA ACC ACC GCA CTG AGG –
(BHQ) 3′ as probe (modified, [35]), respectively. All posi-
tive controls, negative controls and samples were tested in
duplicate. A validated viral DNA (CMVAD169, quantitated
DNA PCR control, cat# 08-925-000, Abionline, MD, USA)
was used as a standard in all experiments. The standard
was serially diluted in ultra pure water from 106 down
to 101 copies/μl and dilutions were freshly prepared
with each run.
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Data analysis
The results were collected from an Access data base
program designed by the director of MICH Central
Laboratory and copied into Excel spread sheets for ana-
lysis. Clinical presentations, data for HCMV viral load
and HCMV avidity were analyzed separately.
Results
In total, 1620 HCMV IgG and 1620 HCMV IgM tests
performed for pregnant women, children, and newborns
during the period from 2006–2012 were analyzed. In
1480 patients (91.4%) both IgG and IgM were tested
simultaneously. In the remaining 8.6% of the patients,
either IgG or IgM was tested. The following analysis was
based only on those cases for which both tests were
obtained simultaneously.
Prevalence of HCMV IgG and IgM
556 (37.6%) of analyzed records were those of pregnant
women in their first trimester, 924 (62.4%) of children,
249 cases (26.9%) of which were newborns (Table 1).
HCMV IgG was positive in 96.6% of women (Figure 1,
Table 1) and in 88% of children respectively (Figure 2,
Table 1). Further evaluation of the children showed that
girls and boys tested equally positive for IgG. In new-
borns, IgG seropositivity was as high as 98.4% (Figure 3,
Table 1).
Regarding the IgM status of pregnant women, 84.7%
were negative, 11.5% were positive and 3.8% were in the
grey zone (Figure 1, Table 1). Five of the 63 IgM-positive
women and two of the 21 grey zone IgM women became
IgM negative when tested one month later. IgG and IgM
were negative in 18 pregnant women (3.2%), while only
one woman (0.2%) out of the total of 556 was negative
for IgG and positive for IgM (Table 2).
Among the children, 11.7% were IgM positive, 85.4%
were negative and 2.9% had IgM values within the grey
zone (Figure 2, Table 1). IgM positive status was 6%
higher in boys than in girls. While 11.3% of children
were IgG and IgM negative, another 11.3% were positive
for both IgG and IgM. Seven children were found to be
negative for IgG and were either positive or in the grey
zone for IgM, while 24 were positive for IgG with grey
zone IgM values (Table 2). Only 2% of the newborns
tested were IgM positive and 0.4% fell into the grey zone
IgM status (Figure 3, Table 1, Table 2).
HCMV avidity
Sera of 40 HCMV IgM-positive women (62.5% of total
IgM-positive women) were tested for HCMV IgG avid-
ity. Twenty-six of these serum samples had been
archived since 2010; the remaining 14 sample belonged
to women who had tested positive for HCMV IgM in
2012. Thirty-nine women (97.5%) were positive for both
IgG and IgM, while only one woman was IgG negative
and IgM positive, for whom IgG avidity could not be
tested. Another woman presented with 44% HCMV IgG
avidity, which is in the grey zone according to the manu-
facturer of the kit. All the other 38 women (95%) pre-
sented with high HCMV IgG avidity (>60%).
Detection of HCMV DNA
The urine of 10 (62.5%) out of 16 newborns (13 were
born to IgM-positive mothers) tested positive for HCMV
Table 1 Status of HCMV serological markers IgG and IgM
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Figure 1 Seroprevalence of IgG and IgM in Palestinian
pregnant women. The percentages of negative, positive and grey
zone (in case of IgM) were calculated using the total number of












IgG- IgG+ IgM- IgM grey IgM+






Figure 2 Seroprevalence of IgG and IgM in hospitalized
Palestinian children. The percentages of negative, positive and
grey zone (in case of IgM) were calculated using the total number
of children tested (924 cases).
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DNA. Viral load for two positive newborns was not
tested at the Virology Research Laboratory. The urine of
15 (83.3%) out of 18 children (all IgM positive) and 3
out of 4 children (IgM grey zone) tested positive for
HCMV DNA.
HCMV viral load was assayed in the whole blood of
another 17 children between the ages of two months and
14 years. Eleven children were HCMV DNA viremic, six
were HCMV IgM positive, while five were HCMV IgM
negative.
Sixteen of the women tested for HCMV avidity were
also tested for HCMV DNA in their sera. While three
women tested negative for HCMV DNA, 13 were viremic
(including the one IgG negative and IgM-positive case).
Clinical observations
Medical charts of all 103 HCMV IgM-positive children,
aged 23 days to 14 years, were reviewed and clinical pre-
sentations suggestive of HCMV infection were recorded.
The major clinical presentations were hepatosplenome-
galy or hepatomegaly (60%), followed by jaundice (30%).
Prolonged fever or fever of unknown origin was re-
corded in 10% of the cases as one of the major clinical
signs, while acute liver failure or fulminant liver failure
presented in 8.7% of the cases. An ophthalmologic exam
was ordered for 33 (32%) children, eight (24.2%) of
whom were suffering from different eye findings,
including chorioretinal spots, bilateral mild cataract, bi-
lateral optic atrophy and bilateral choroidal coloboma.
Hearing was impaired in one case. Nevertheless, out of
all 103 children cases, only a single case, a two month-
old child, suffering from progressive intrahepatic chole-
stasis was treated with Gancyclovir.
Medical registers of all 249 newborns tested for
HCMV serology were reviewed. Sixteen newborns were
subjected to HCMV viral load testing in urine; thirteen
were born to mothers with recurrent HCMV infection.
The remaining three newborns were admitted to MICH
following birth (aged 1, 10 and 19 days) and tested for
HCMV because of symptomatic congenital infection.
The only cases treated with Gancyclovir, because of
symptomatic congenital HCMV infection, along with
viral shedding in urine, were one newborn born at
MICH to a mother with recurrent HCMV infection and
the three newborns admitted following birth. The first
case suffered from HCMV chorioretinitis, the one-day-
old newborn presented with microcephaly and intracere-
bral calcification, the 10-day-old infant (HCMV IgM
positive) suffered from hepatosplenomegaly and neonatal
jaundice, while the 19-day-old infant (HCMV IgM posi-
tive) presented with cholestatic jaundice and neuro-
logical manifestation. Interestingly, two of the mothers,
whose newborns were admitted, tested positive for
HCMV IgM on the admission of their infants (1-day and
10-day-olds). Finally, all infants, born at MICH to
HCMV IgM-positive mothers were discharged with
recommendations to follow up with ophthalmic test and
auditory brain stem evoked response (ABER) hearing
test, even when HCMV DNA in their urine was negative
and congenital symptoms were absent.
Discussion
The seroprevalence of HCMV IgG among pregnant
Palestinian women and children as presented here is
comparable to regional studies from Egypt [36], Qatar
[30], Tunisia [37], Bahrain [38], Iraq [39], Iran [4],Turkey
[28], [29]) and ranks among countries with high sero-
prevalence, comparable to Brazil, Cuba, Japan and
Taiwan [24-27,40,41]. Lower regional seroprevalence is
reported from Sudan at a rate of 72% among pregnant
Table 2 Verified HCMV IgG/IgM status in the study population
Population Pregnant Women Children (total) Newborns only
Immunoglobulin IgG+ IgG- IgG+ IgG- IgG+ IgG-
n (%) n (%) n (%) n (%) n (%) n (%)
IgM+ 63 (11.3) 1 (0.2) 104 (11.3) 4 (0.4) 5 (2) 0 (0)
IgM- 453 (81.5) 18 (3.2) 685 (74.1) 104 (11.3) 239 (96) 4 (1.6)
IgM grey 21 (3.8) 0 (0) 24 (2.6) 3 (0.3) 1 (0.4) 0 (0)
Pregnant women (556), children (924) including newborns (249) are indicated; number of cases (n) subjected to HCMV IgG and IgM testing is given, while the
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Figure 3 Seroprevalence of IgG and IgM in hospitalized
Palestinian newborns. The percentages of negative, positive and
grey zone (in case of IgM) were calculated using the total number
of newborn tested (249 cases).
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women [42] and Syria at a rate of 74.5% among college
female students [43]. The seroprevalence among women
in Israel varies based on ethnical groups. It has been
shown to be as high as 80% in women of Afro-Asian ori-
gin and 65% in those of European-American origin [32].
The percentages are in fact 15% higher in both ethnic
groups of women living in a Kibbutz environment [32].
The high level of IgG among newborns presented in this
study is in accordance with earlier studies from regions
of high maternal seroprevalence [27,36], normally due to
placental transfer of maternal antibodies [44]. Taking
into consideration the seroprevalence in children de-
scribed here, we propose that the number of HCMV
IgG-positive newborns would decline during the first
months/years of childhood, to rise again in later child-
hood. Indeed, this has been observed in a recent study
on HCMV IgG kinetics in Chinese newborns, where ma-
ternal seroprevalence is high [45].
The percentage of active infection (positive HCMV
IgM) among pregnant Palestinian women is 3–5 times
higher than that described in regional studies from Iran
[4], Qatar [30], Sudan [42] and Turkey [28,29] or even
international studies from Belgium, Brazil, Cuba, Finland
and Taiwan [19,24,27,40,46]. A similar rate of active
infection has been reported from Poland [47] and in one
study from India [48]. The highly accurate AxSYM IgM
test at MICH is a contributing technical factor for the
high rate of positivity for IgM, as previously described
[49]. Interestingly, only one woman (2.5%) out of the 40
IgM-positive Palestinian women tested was IgG negative,
indicating a primary infection, while 38 (95%) presented
with high HCMV IgG avidity. These data illuminate that
recurrent infection among pregnant Palestinian women
is the leading cause for this high level of active infection.
Molecular biology studies are recommended to deter-
mine whether the recurrent infection is caused by a
reactivation of a latent virus or reinfection with a new
HCMV strain.
The percentage of positive HCMV IgM among hospi-
talized Palestinian children at MICH is also higher than
percentages reported in a control group from Iraq [39]
and Qatar [30]. Here, the high sensitivity of AxSYM IgM
test is also a contributing technical factor for the high
rate of positivity for IgM [49]. However, as mentioned in
the methods section, MICH is the referral hospital in
Palestine, so that children admitted to the pediatric ward
are predominantly those with intractable medical condi-
tions. Therefore, this IgM positive percentage and the
high rate of HCMV viral load in urine and blood cannot
be generalized to Palestinian children as an overall
population. On the other hand, we propose that the
medical conditions of at least a portion of these hospital-
ized children who tested positive for HCMV viremia or
viral shedding in urine, as previously suggested, could be
attributed to sequelae of undetected HCMV congenital
infection [50,51].
Since vertical transmission of HCMV is 15-20% higher
in primary infected women compared to women with re-
current infection [9,11,12,52], Palestinian infants may be
considered at lower risk of perinatal HCMV infection, as
most pregnant Palestinian women appear to suffer from
recurrent infection. However, data from a recent study
from in Israel demonstrates that the percentage of verti-
cal transmission in women with recurrent infection is
19.6%, which is much higher than earlier estimations of
2.2% [53]. A large-scale study performed in Brazil has
documented that the frequency of congenital HCMV
disease in populations with high seroprevalence is higher
than those with low seroprevalence [54]. In fact, a very
recent review concludes that maternal HCMV seroposi-
tivity is a risk factor for congenital HCMV infection and
HCMV-related hearing loss in children [55]. Taking
these studies into consideration, the incidence of con-
genital HCMV infection in Palestine is probably under-
estimated due to the lack of large-scale studies. During
this study period, four (1.6%) HCMV congenital infec-
tions out of 249 tested newborns were symptomatic, and
thus were treated with Gancyclovir. This percentage
does not reflect a true incidence rate of symptomatic
congenital HCMV infection among Palestinian new-
borns, as not all women tested at MICH gave birth at
the facility and three of these infants were admitted
to MICH following birth. Viral shedding in urine was
detected in another six babies, born to HCMV IgM-
positive mothers, which may be associated with high risk
of hearing loss in later childhood [56-58]. However, we
have no records regarding the follow-up examinations,
as most cases elect to consult physicians outside the
MICH clinical facilities after discharge.
We have no records regarding the socioeconomic sta-
tus (SES) of the women and children, whose results are
presented here. Reports from various countries have
shown that SES is proportional to the high rate of
HCMV infection [9,13,21,33,46,59,60]. We have no evi-
dence for SES playing such a critical role in the high rate
of HCMV seroprevalence in Palestine. Therefore we
propose rather that Palestinian social habits and living
conditions may be the driving factor contributing to the
high incidence of seroprevalence of HCMV.
Conclusions
Screening pregnant women for HCMV IgG and IgM is
not performed routinely in Palestine; MICH policy is
thereby an exception. The data provided here and that
of other studies strongly encourage routine testing for
HCMV IgG and IgM among pregnant women in
Palestine. Finally, follow-up tests with offspring to
HCMV IgM-positive mothers are essential, in order to
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detect the consequences of congenital infection and to
allow treatment to occur as early as possible.
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